methyl 2-(3-chlorophenyl)-2-hydroxyacetate | 13305-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(3-chlorophenyl)-2-hydroxyacetate
• CAS: 13305-18-5
• 化学式: C₉H₉ClO₃
• mdl: MFCD16693824
• 分子量: 200.622
• InChiKey: CPEZVACFWJSZNE-UHFFFAOYSA-N

物化性质

• 熔点：
  84 °C
• 沸点：
  296.0±25.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(3-chlorophenyl)-2-hydroxyacetate 在 二溴亚砜 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.17h， 生成 methyl (RS)-(3-chlorophenyl)-[2-cyano-5-(thien-3-ylmethoxy)phenoxy]acetate
  参考文献：
  名称：

  Selective ET_A Antagonists. 5. Discovery and Structure−Activity Relationships of Phenoxyphenylacetic Acid Derivatives

  摘要：

  The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ETA receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ETA antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC50 59 nM, rat aortic ETA). Optimization of 13a led to the identification of 27b, which exhibited an IC50 of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 mu mol/kg) and was duly proposed and accepted as a development candidate.

  DOI：

  10.1021/jm990378b
• 作为产物：
  描述：

  methyl 2-(3-chlorophenyl)-2-oxoacetate 在 甲醇 、 苯甲醛 、 1,3-双(2,4,6-三甲基苯基)氯化咪唑 、 三乙胺 作用下， 反应 5.0h， 以95%的产率得到methyl 2-(3-chlorophenyl)-2-hydroxyacetate
  参考文献：
  名称：

  1,3-Bis(2,4,6-trimethylphenyl)imidazolium chloride in combination with triethylamine: an improved catalytic system for hydroacylation/reduction of activated ketones

  摘要：

  A rapid, economic, and high yielding methodology has been developed for hydroacylation/reduction of activated ketones by using 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride as a catalyst in combination with triethylamine. The reaction proceeded at an ambient temperature via generating N-heterocyclic carbene in situ that interacted with the (hetero)aryl aldehyde employed. While the reduction of ketones takes place in MeOH, the hydroacylation process was found to be effective in THF for both electron rich and deficient aldehydes. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.12.022

文献信息

• Kinetic resolution of mandelate esters via stereoselective acylation catalyzed by lipase PS-30
  作者：Peiran Chen、Wenhong Yang

  DOI：10.1016/j.tetlet.2014.02.095

  日期：2014.4

  By using lipase PS-30 as catalyst, the kinetic resolution of a series of racemic mandelate esters has been achieved via stereoselective acylation. The value of kinetic enantiomeric ratio (E) reached up to 197.5. Substituent effect is briefly discussed.

  通过使用脂肪酶PS-30作为催化剂，已通过立体选择性酰化反应实现了一系列外消旋扁桃酸酯的动力学拆分。动力学对映体比率（E）的值达到197.5。简要讨论了取代基的作用。
• New 4-aryl-1,3,2-oxathiazolylium-5-olates: Chemical synthesis and photochemical stability of a novel series of S-nitrosothiols
  作者：Monica Eilertsen、Steve M. Allin、Russell J. Pearson

  DOI：10.1016/j.bmcl.2018.01.059

  日期：2018.4

  –SNO moiety into a five membered heterocyclic ring in an attempt to improve the compound’s overall stability. The synthesis of a novel series of halogen-containing OZOs was comprehensively studied resulting in a seven-step route and overall yields ranging between 21 and 37%. The photochemical stability of these compounds was assessed to determine if S-nitrosothiols locked within these mesoionic ring systems

  S-亚硝基硫醇（RSNO）仍然是最流行的NO供体化合物之一，因为它们能够在非酶促方式下释放一氧化二氮（NO），同时产生惰性的二硫化物副产物。然而，由于这些化合物在包括热，光和铜离子存在在内的各种条件下固有的不稳定性，将这些化合物归入NO研究的不同生物学领域已被证明是有问题的。1,3,2-氧杂恶唑基-5-油酸酯（OZO）代表S的一个有趣子类-亚硝基硫醇将–SNO部分锁定在五元杂环中，以试图改善化合物的整体稳定性。全面研究了一系列新型的含卤素OZO的合成，得出了七步路线，总收率在21％到37％之间。评估了这些化合物的光化学稳定性，以确定与这些非环状对应物相比，锁定在这些中离子环系统内的S-亚硝基硫醇是否可以提供更高的稳定性，从而以更可控的方式释放NO。
• VITAMIN D-LIKE COMPOUND
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1894911A1

  公开（公告）日：2008-03-05

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。
• [EN] HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] HETEROCYCLES UTILISES COMME INHIBITEURS DE MDM2 DANS LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2013049250A1

  公开（公告）日：2013-04-04

  The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了化合物I或II的MDM2抑制剂，或其药用盐，其中上述变量已定义，这些化合物可用作治疗剂，特别用于癌症的治疗。本发明还涉及含有MDM2抑制剂的药物组合物。
• Kinetic Resolution of Allylic Alcohol with Chiral BINOL-Based Alkoxides: A Combination of Experimental and Theoretical Studies
  作者：Yidong Liu、Song Liu、Dongmei Li、Nan Zhang、Lei Peng、Jun Ao、Choong Eui Song、Yu Lan、Hailong Yan

  DOI：10.1021/jacs.8b12796

  日期：2019.1.16

  enantioselective catalytic kinetic resolution of allylic alcohols through asymmetric isomerization with chiral BINOL derivatives-based alkoxides as bifunctional Brønsted base catalysts were described in the study. A number of chiral BINOL derivatives-based alkoxides were synthesized, and their structure-enantioselectivity correlation study in asymmetric isomerization identified a promising chiral Brønsted

  该研究描述了使用手性 BINOL 衍生物基醇盐作为双功能 Brønsted 碱催化剂通过不对称异构化对烯丙醇进行对映选择性催化动力学拆分的开发和表征。合成了许多基于手性 BINOL 衍生物的醇盐，它们在不对称异构化中的结构-对映选择性相关性研究确定了一种有前途的手性 Brønsted 碱催化剂，它提供了各种手性仲烯丙醇（ee 高达 99%，S 因子高达 >200 ）。在机理研究中，醇盐物种被确定为活性物种，而 BINOL 的酚基通过手性 Brønsted 碱催化剂和底物之间的氢键极大地影响了高反应性和对映选择性。该策略是第一个通过对映选择性无过渡金属碱催化异构化成功合成各种手性仲烯丙醇的策略。生物活性天然产物 (+)-veraguensin 的合成证明了该策略的适用性。